| Ytd | -9.23% | |
| 1y | 82.20% |
| Open | 71.37 | Prev Close | 72.81 | Low | 70.84 | High | 72.13 | Mkt Cap | 695.09M |
| Vol | 29.12K | Avg Vol | 288.83K | EPS | -2.05 | P/E | N/A | Forward P/E | N/A |
| Beta | -5.27 | Short Ratio | 0.70 | Inst. Own | 44.28% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-17 | 50-d Avg | 73.91 | 200-d Avg | 77.59 | 1yr Est | 4.87 |
DRUG News
Does Bright Minds Biosciences Inc. (DRUG) have what it takes to be a top stock pick for momentum inv
The average of price targets set by Wall Street analysts indicates a potential upside of 97% in Brig
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Bright Minds Biosciences (NASDAQ:D
BTIG analyst Thomas Shrader reiterates Bright Minds Biosciences (NASDAQ:DRUG) with a Buy and main
The mean of analysts' price targets for Bright Minds Biosciences Inc. (DRUG) points to a 97.4% upsid
SOUTH SAN FRANCISCO, Calif., July 31, 2026 (GLOBE NEWSWIRE) -- Vistagen (Nasdaq: VTGN), a late clini
The consensus price target hints at a 107.5% upside potential for Bright Minds Biosciences Inc. (DRU
Bright Minds Biosciences Inc. (DRUG) might move higher on growing optimism about its earnings prospe
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Bright Minds Biosciences (NASDAQ:D
NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or
Bright Minds Biosciences develops serotonin-based therapeutics for neurological and neuropsychiatric
Piper Sandler analyst Yasmeen Rahimi maintains Bright Minds Biosciences (NASDAQ:DRUG) with a Over
https://www.hhs.gov/press-room/fda-accelerates-action-treatments-serious-mental-illness-following-ex
https://www.cbsnews.com/news/psychedelic-drug-ibogaine-ptsd-trump-to-sign-executive-order/
Jefferies analyst Andrew Tsai initiates coverage on Bright Minds Biosciences (NASDAQ:DRUG) with a
BTIG analyst Thomas Shrader reiterates Bright Minds Biosciences (NASDAQ:DRUG) with a Buy and main
Bright Minds Biosciences Inc. (NASDAQ: DRUG - Get Free Report) has been given a consensus recommenda
https://www.marijuanamoment.net/bipartisan-senators-file-bill-to-support-psychedelics-research-and-t
HC Wainwright & Co. analyst Patrick R. Trucchio maintains Bright Minds Biosciences (NASDAQ:DR
NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or
BTIG analyst Thomas Shrader maintains Bright Minds Biosciences (NASDAQ:DRUG) with a Buy and maint
Bright Minds Biosciences Inc. (NASDAQ: DRUG - Get Free Report) has been assigned an average rating o
Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) ("Bright Minds" or the "Company&#
NEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG)
NEW YORK, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG)
Bright Minds Biosciences remains a "Strong Buy" after positive phase 2 data for BMB-101 in drug-resi
BTIG analyst Thomas Shrader maintains Bright Minds Biosciences (NASDAQ:DRUG) with a Buy and raise
-- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) ("Bright Minds" or the "Compan
NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG)
BTIG analyst Thomas Shrader maintains Bright Minds Biosciences (NASDAQ:DRUG) with a Buy and raise
Bright Minds Biosciences Inc. (NASDAQ: DRUG) stock is trading higher on Tuesday after the company sh
Bright Minds' stock rose after its epilepsy drug cut seizures in a Phase 2 trial, showed good sa
BMB-101 demonstrated significant anti-seizure benefit in both cohorts with favorable safety and tole
NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (Nasdaq: DRUG)
Shares of Bright Minds Biosciences Inc (NASDAQ: DRUG, CSE:DRUG) jumped almost 25% after the company
– Conference Call and Live Webcast at 8AM ET – NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Bright Mi
Bright Minds Biosciences Inc. (NASDAQ: DRUG - Get Free Report)'s share price rose 4.2% during tradin
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Bright Minds Biosciences (NASDAQ:D
https://www.marijuanamoment.net/psychedelics-show-promise-as-an-entirely-new-type-of-anti-inflammato
https://www.marijuanamoment.net/new-york-lawmakers-hold-hearing-psilocybins-medical-benefits-amid-br
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Bright Minds Biosciences (NASDAQ:D
https://www.marijuanamoment.net/massachusetts-lawmakers-approve-bill-to-create-psychedelic-therapy-p
BTIG initiates coverage on Bright Minds Biosciences with a Buy rating, citing BMB‑101's potentia